Evaluation of the nephroprotective effect of dapagliflozin in renal ischaemia-reperfusion injury in male rats: Foxo1 modulation and pyroptosis
DOI:
https://doi.org/10.60988/p.v37i2S.139Keywords:
renal ischaemia-reperfusion; dapagliflozin; nephroprotection; pyroptosis; FOXO1Abstract
Renal ischaemia-reperfusion injury (RIRI) significantly contributes to acute kidney injury, leading to high morbidity and mortality rates. This study has investigated the nephroprotective effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on RIRI in male Wistar rats. Twenty four rats were divided into four groups (n=6 each): a sham group (without an induction of RIRI), a control group (with an induction of RIRI), a vehicle group (receiving an intraperitoneal injection of 10% v/v dimethyl sulfoxide in isotonic saline solution, 1 h before ischaemia), and a dapagliflozin-treated group (receiving an intraperitoneal injection of dapagliflozin at 1 mg/kg, 1 h before ischaemia). Ischaemia was induced by clamping the renal pedicles for 30 min, followed by 2 h of reperfusion. Histopathological analysis revealed marked renal tissue injury in the control and vehicle groups, while dapagliflozin administration reduced these injuries, suggesting that less than 50% of the renal tubules were affected as a result. Kidney injury molecule-1, caspase-1, and caspase-11 levels were found to be significantly elevated in the control and vehicle groups, but decreased in the dapagliflozin group. The forkhead box O1 gene (Foxo1) expression was also found significantly reduced as a result of the treatment. These findings suggest that dapagliflozin mitigates renal injury through the suppression of Foxo1 expression and pyroptosis, thereby improving renal cell integrity. This study highlights dapagliflozin’s potential as a nephroprotective agent against acute renal failure, as it can enhance renal cell survival and mitigate injury pathways.
References
References
Alaasam E.R., Janabi A.M., Al-Buthabhak K.M., Almudhafar R.H., Hadi N.R., Alexiou A., et al. Nephroprotective role of resveratrol in renal ischemia-reperfusion injury: a preclinical study in Sprague-Dawley rats. BMC Pharmacol. Toxicol. 25(1), 82, 2024. DOI: 10.1186/s40360-024-00809-8
Mahmood K.A., Ewadh M.J., Al-Saad S.F. The role of IGFBP-7 in predicting contrast-induced acute kidney injury. Front. Health Inform. 13(4), 497–502, 2024.
Jallawee H.Q., Janabi A.M. Potential nephroprotective effect of dapagliflozin against renal ischemia reperfusion injury in rats via activation of autophagy pathway and inhibition of inflammation, oxidative stress and apoptosis. South East. Eur. J. Public Health 24(s2), 488–500, 2024. DOI: 10.70135/seejph.vi.1009
Zhou Z., Li Q. The role of pyroptosis in the pathogenesis of kidney diseases. Kidney Dis. (Basel) 9(6), 443–458, 2023. DOI: 10.1159/000531642
Abd-Ulhussein H.K., Rizij F.A.J. Evaluation of the effect of dapagliflozin on atherosclerosis progression by interfering with inflammatory and oxidative stress pathways in rabbits. Med. J. Babylon 16(1), 20–24, 2019. DOI: 10.4103/MJBL.MJBL_104_18
Cheng Z. FoxO transcription factors in mitochondrial homeostasis. Biochem. J. 479(4), 525–536, 2022. DOI: 10.1042/BCJ20210777
Al-Mubarak B., Soriano F.X., Hardingham G.E. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) 3(4), 233–238, 2009. DOI: 10.4161/chan.3.4.9381
Younis S.S., Ghafil F.A.A., Majeed S., Hadi N.R. NHWD-870 protects the kidney from ischemia/reperfusion injury by upregulating the PI3K/AKT signaling pathway (experimental study). J. Med. Life 16(6), 925–931, 2023. DOI: 10.25122/jml-2022-0309
Xu S., Wang J., Zhong J., Shao M., Jiang J., Song J., et al. CD73 alleviates GSDMD-mediated microglia pyroptosis in spinal cord injury through PI3K/AKT/Foxo1 signaling. Clin. Transl. Med. 11(1), e269, 2021. DOI: 10.1002/ctm2.269
